Your browser doesn't support javascript.
A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity.
Yang, Ren; Deng, Yao; Huang, Baoying; Huang, Lei; Lin, Ang; Li, Yuhua; Wang, Wenling; Liu, Jingjing; Lu, Shuaiyao; Zhan, Zhenzhen; Wang, Yufei; A, Ruhan; Wang, Wen; Niu, Peihua; Zhao, Li; Li, Shiqiang; Ma, Xiaopin; Zhang, Luyao; Zhang, Yujian; Yao, Weiguo; Liang, Xingjie; Zhao, Jincun; Liu, Zhongmin; Peng, Xiaozhong; Li, Hangwen; Tan, Wenjie.
  • Yang R; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Deng Y; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Huang B; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Huang L; Stemirna Therapeutics, Shanghai, China.
  • Lin A; Stemirna Therapeutics, Shanghai, China.
  • Li Y; National Institute for Food and Drug Control, Beijing, China.
  • Wang W; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Liu J; National Institute for Food and Drug Control, Beijing, China.
  • Lu S; National Kunming High-level Primate Research Center, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Yunnan, China.
  • Zhan Z; Shanghai East Hospital, Tongji University, Shanghai, China.
  • Wang Y; CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and National Center for Nanoscience and Technology of China, Beijing, China.
  • A R; University of Chinese Academy of Sciences, Beijing, China.
  • Wang W; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Niu P; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Zhao L; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Li S; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Ma X; Stemirna Therapeutics, Shanghai, China.
  • Zhang L; Stemirna Therapeutics, Shanghai, China.
  • Zhang Y; Stemirna Therapeutics, Shanghai, China.
  • Yao W; Stemirna Therapeutics, Shanghai, China.
  • Liang X; Stemirna Therapeutics, Shanghai, China.
  • Zhao J; CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and National Center for Nanoscience and Technology of China, Beijing, China.
  • Liu Z; University of Chinese Academy of Sciences, Beijing, China.
  • Peng X; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
  • Li H; Shanghai East Hospital, Tongji University, Shanghai, China.
  • Tan W; National Kunming High-level Primate Research Center, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Yunnan, China. pengxiaozhong@pumc.edu.cn.
Signal Transduct Target Ther ; 6(1): 213, 2021 05 31.
Article in English | MEDLINE | ID: covidwho-1249203
ABSTRACT
Although inoculation of COVID-19 vaccines has rolled out globally, there is still a critical need for safe and effective vaccines to ensure fair and equitable supply for all countries. Here, we report on the development of a highly efficacious mRNA vaccine, SW0123 that is composed of sequence-modified mRNA encoding the full-length SARS-CoV-2 Spike protein packaged in core-shell structured lipopolyplex (LPP) nanoparticles. SW0123 is easy to produce using a large-scale microfluidics-based apparatus. The unique core-shell structured nanoparticle facilitates vaccine uptake and demonstrates a high colloidal stability, and a desirable biodistribution pattern with low liver targeting effect upon intramuscular administration. Extensive evaluations in mice and nonhuman primates revealed strong immunogenicity of SW0123, represented by induction of Th1-polarized T cell responses and high levels of antibodies that were capable of neutralizing not only the wild-type SARS-CoV-2, but also a panel of variants including D614G and N501Y variants. In addition, SW0123 conferred effective protection in both mice and non-human primates upon SARS-CoV-2 challenge. Taken together, SW0123 is a promising vaccine candidate that holds prospects for further evaluation in humans.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies Topics: Vaccines / Variants Limits: Animals / Female / Humans Language: English Journal: Signal Transduct Target Ther Year: 2021 Document Type: Article Affiliation country: S41392-021-00634-z

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies Topics: Vaccines / Variants Limits: Animals / Female / Humans Language: English Journal: Signal Transduct Target Ther Year: 2021 Document Type: Article Affiliation country: S41392-021-00634-z